Q2 EPS Estimates for OPKO Health Decreased by HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – HC Wainwright reduced their Q2 2025 EPS estimates for shares of OPKO Health in a research note issued on Monday, March 3rd. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.08) per share for the quarter, down from their prior estimate of ($0.07). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.31) EPS.

A number of other research firms have also commented on OPK. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday, February 28th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd.

OPKO Health Price Performance

OPK stock opened at $1.90 on Thursday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health has a one year low of $0.86 and a one year high of $2.04. The firm has a market capitalization of $1.30 billion, a PE ratio of -10.00 and a beta of 1.63. The firm has a 50-day moving average of $1.58 and a two-hundred day moving average of $1.56.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The company had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million.

Insider Activity

In other news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were purchased at an average price of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the acquisition, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at approximately $313,384,121.19. This represents a 0.07 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have acquired 1,389,971 shares of company stock worth $2,124,442 in the last 90 days. Company insiders own 47.26% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in OPKO Health by 4.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after buying an additional 8,064 shares during the last quarter. Two Sigma Advisers LP increased its holdings in OPKO Health by 2.3% in the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,396 shares during the last quarter. FMR LLC increased its holdings in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the last quarter. Comerica Bank increased its holdings in OPKO Health by 18.2% in the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock worth $156,000 after buying an additional 16,369 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in OPKO Health by 4.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock worth $670,000 after buying an additional 18,571 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.